Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

A Multicompartment Human Kidney Proximal Tubule-on-a-Chip Replicates Cell Polarization–Dependent Cisplatin Toxicity

Tom T.G. Nieskens, Mikael Persson, Edward J. Kelly and Anna-Karin Sjögren
Drug Metabolism and Disposition December 2020, 48 (12) 1303-1311; DOI: https://doi.org/10.1124/dmd.120.000098
Tom T.G. Nieskens
CVRM Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden (T.T.G.N., M.P., A.-K.S.) and Department of Pharmaceutics and Kidney Research Institute, University of Washington, Seattle, Washington (E.J.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikael Persson
CVRM Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden (T.T.G.N., M.P., A.-K.S.) and Department of Pharmaceutics and Kidney Research Institute, University of Washington, Seattle, Washington (E.J.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward J. Kelly
CVRM Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden (T.T.G.N., M.P., A.-K.S.) and Department of Pharmaceutics and Kidney Research Institute, University of Washington, Seattle, Washington (E.J.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Karin Sjögren
CVRM Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden (T.T.G.N., M.P., A.-K.S.) and Department of Pharmaceutics and Kidney Research Institute, University of Washington, Seattle, Washington (E.J.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 48 no. 12 1303-1311
DOI 
https://doi.org/10.1124/dmd.120.000098
PubMed 
33020068

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received April 24, 2020
  • Accepted September 23, 2020
  • Published online November 18, 2020.

Article Versions

  • Earlier version (October 5, 2020 - 13:47).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Tom T.G. Nieskens1,
  2. Mikael Persson1,
  3. Edward J. Kelly2,3, and
  4. Anna-Karin Sjögren1
  1. CVRM Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden (T.T.G.N., M.P., A.-K.S.) and Department of Pharmaceutics and Kidney Research Institute, University of Washington, Seattle, Washington (E.J.K.)
  1. Address correspondence to:
    Anna-Karin Sjögren, AstraZeneca R&D Mölndal, Pepparedsleden 1, 43150 Mölndal, Sweden. E-mail: anna-karin.sjogren{at}astrazeneca.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: October 2020 to January 2021

AbstractFullPdf
Oct 20204245172
Nov 20202673172
Dec 20201974092
Jan 2021801428

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 48 (12)
Drug Metabolism and Disposition
Vol. 48, Issue 12
1 Dec 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Multicompartment Human Kidney Proximal Tubule-on-a-Chip Replicates Cell Polarization–Dependent Cisplatin Toxicity
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Polarization Determines Kidney-on-a-Chip Cisplatin Toxicity

Tom T.G. Nieskens, Mikael Persson, Edward J. Kelly and Anna-Karin Sjögren
Drug Metabolism and Disposition December 1, 2020, 48 (12) 1303-1311; DOI: https://doi.org/10.1124/dmd.120.000098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Polarization Determines Kidney-on-a-Chip Cisplatin Toxicity

Tom T.G. Nieskens, Mikael Persson, Edward J. Kelly and Anna-Karin Sjögren
Drug Metabolism and Disposition December 1, 2020, 48 (12) 1303-1311; DOI: https://doi.org/10.1124/dmd.120.000098
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics